Deep Brain Stimulation for Parkinson's Disease: Where Do We Stand?

Deep brain stimulation (DBS) is an established treatment for Parkinson's disease (PD) patients who present with disabling motor complications, such as fluctuations and dyskinesias unmanageable by medical treatment alone (The Deep-Brain Stimulation for Parkinson's Disease Study Group, 2001). In recent years, two main targets have emerged: the subthalamic nucleus (STN) and the globus pallidum internum (GPi). These brain nuclei differ significantly for anatomical connections, size, and functional role within the basal ganglia. The available clinical experience, arising either from mono-center or multi-center studies, is more detailed for STN compared to GPi DBS. First, short-term data have shown that, compared to best medical treatment, STN stimulation is more efficacious for controlling dyskinesias, motor function, and quality of life, but is associated with a higher risk of serious adverse events (Deuschl et al., 2006). Furthermore, long-term sustained motor efficacy of STN implants has been demonstrated for up to 8 years now (Fasano et al., 2010), compared to 5.5 years of GPi (Moro et al., 2010b). Medication- and stimulation-resistant symptoms, mainly axial signs (such as gait and postural impairment) become evident after 5 years after STN implants. These features are likely due to disease progression, which also require either the increase of dopaminergic medication dosage or of the total electrical energy delivered to the STN (Fasano et al., 2010). Three recent studies (two randomized and one uncontrolled) have compared the effects of STN and GPi stimulation in complicated PD patients (Table ​(Table1). 1). Taken together, they indicate that STN and GPi stimulations have similarities and differences. They both improve motor signs of PD and reduce dyskinesias; however, STN stimulation generates more pronounced motor improvement allowing to reduce dopaminergic medication to a higher degree. The trade-off is a higher incidence of treatment-related adverse events, in particular speech disturbances and post-operative confusion, in patients receiving STN implants. These trials have intrinsic methodological limitations that curb their external validity, particularly due to the multi-center design with heterogeneity of targeting techniques, equipment, selection criteria, and post-operative procedures. Currently, most centers in Europe and in North America perform implants in the STN rather than in the GPi; in most instances, this preference is based on the team experience. Recent data indicate, however, that target selection could be tailored to the patient's clinical and personal profile: GPi DBS may suit better patients with dose-limiting dyskinesias or behavioral and cognitive issues, whereas STN DBS may be more indicated for younger patients with prominent akinesia and tremor or with behavioral disorders related to dopaminergic medication. Table 1 Published data comparing bilateral GPi and STN implants in PD. Non-motor features may provide predictive information on long-term STN DBS efficacy. A recent prospective study showed that the occurrence of REM sleep behavior disorder in PD patients undergoing STN DBS may be per se associated with a less favorable outcome and a more prominent development of axial symptoms over time (Zibetti et al., 2010); by contrast, cardiovascular dysautonomia is compatible with satisfactory motor outcome, as reported 1 year after STN DBS (Holmberg et al., 2005). The observation of a decay of motor outcome 8 year after STN implants (Fasano et al., 2010) raises the issue whether surgery should be considered an earlier therapeutic option, being also performed on patients with uncomplicated PD. The rationale would be to maximize motor benefit and spare dopaminergic medication before disability accumulates and the quality of personal and social life decays. Most implanting centers apply patients selection criteria stated by the CAPSIT-PD committee (Defer et al., 1999) that recommend to select patients with at least 5 years of disease duration, with significant motor disability and no cognitive or psychiatric impairment. No recommendation is available on age or disease duration limits for STN or GPi implants. The few studies addressing the effects of age or disease duration at time of implant proved to be inconclusive. An uncontrolled study has identified age and pre-operative levodopa responsiveness and, to a lesser extent, disease duration, as predictors of outcome for bilateral STN DBS (Charles et al., 2002). This was not confirmed by a systematic review that found no evidence of better surgical outcome in younger patients who received STN DBS (Kleiner-Fisman et al., 2006). More recently, it has been agreed that the overall motor improvement is unrelated to age at time of implant (Derost et al., 2007), although quality of life improvements occur only in younger patients. The question as to when is the optimal timing for DBS implants remains very concrete. An 18-month prospective trial significantly favored early DBS over early medical therapy alone in measures of quality of life, motor performance without medication, levodopa-induced motor complications, and medication reduction (Schupbach et al., 2007). The adverse events were mild or transient, and overall psychiatric morbidity and anxiety improved more in the surgical group. This study suggested that treating younger patients before symptoms become disabling should help many remain productive longer than without surgery, making surgery an ethically acceptable option for younger, less severely compromised patients. Two randomized controlled trials aimed at assessing the usefulness of early STN DBS are currently underway: the EARLYSTIM multi-center German–French study (ClinicalTrials.gov {"type":"clinical-trial","attrs":{"text":"NCT00354133","term_id":"NCT00354133"}}NCT00354133) and the North American mono-center study (ClinicalTrials.gov {"type":"clinical-trial","attrs":{"text":"NCT00282152","term_id":"NCT00282152"}}NCT00282152). The results of these trials are expected not before a couple of years. A reason for performing STN implants earlier also stems by the aim to prevent the occurrence of a dopaminergic dysregulation syndrome. Data regarding the effect of STN DBS on dopamine dysregulation, impulse control disorders, and punding in PD are still limited and conflicting: available observations report that these features may develop after DBS, or otherwise improve, persist, or worsen (Bandini et al., 2007; Lim et al., 2009). The main issue to solve is what factors allow predicting behavioral variations after implants. A likely hypothesis is that medication or DBS may differentially affect some preexisting personality features; medication dosage and stimulation settings may represent key variables of outcome. There is also evidence that STN DBS causes executive inhibitory deficits and impulsive behavior under high-conflict conditions; these phenomena are probably due to an impulsive decision-making that may be explained by an inability to self-modulate decision times as a function of conflict (Frank et al., 2007). STN DBS may act directly on the gating mechanism involved in response initiation and proactive inhibitory commands (Ballanger et al., 2009). It is not known whether these phenomena are affected by patients’ age or disease duration. In recent years, other potential targets for PD have been investigated. Experimental findings suggest that low frequency DBS of the pedunculopontine nucleus (PPN) could improve some of the axial symptoms of the disease unresponsive to STN DBS and dopaminergic therapy, particularly freezing of gait and the frequency of falls (Moro et al., 2010a), but the results of a recent double-blind cross-over study (Ferraye et al., 2010) have frozen expectations. Simultaneous STN and PPN stimulation has also been performed with the aim to provide better motor control to patients (Stefani et al., 2007). New devices will allow controlling four or more electrodes, allowing to perform simultaneous multiple target stimulation with just one implantable pulse generator. The most expected innovation, however, is technical. In order to optimize the efficacy of DBS and reduce unwanted current spread to adjacent brain structures, electrodes need to be redesigned and active contacts should have improved geometry. Nanotechnology will permit a progressive miniaturization of hardware components and ideally the improvement of lengthy connecting cables and distant pulse generators. The development of sensor-driven pacing has been a landmark innovation for cardiac pacemakers, enabling the device to respond to physiologic demands. Similarly, the development of responsive DBS stimulators, would allow moving beyond the current paradigms of treatment, toward a stimulation adjusted to motor context and movement needs, a physiological function that cannot be provided by medication.